SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories’ business growth to be volatile in FY22

05 Jul 2021 Evaluate

Dr. Reddy's Laboratories is expecting its business growth to be volatile in FY22 as the coronavirus pandemic continues to bring in disruptions and impact the markets across the globe. Despite various challenges in the market, it has enough growth levers to deliver satisfactory performance in terms of business growth this fiscal.

For the 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20. Its net sales increased to Rs 18,420 crore during the last fiscal year as compared with Rs 16,357 crore in 2019-20.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Labs. Share Price

1348.95 -27.35 (-1.99%)
30-Jun-2026 10:17 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1883.85
Dr. Reddys Labs. 1348.95
Cipla 1458.95
Zydus Lifesciences 1121.75
Lupin 2385.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: